Alaunos Therapeutics Inc stock is traded at $1.61, with a volume of 100,120. It is down -5.85% in the last 24 hours and up +53.33% over the past month. Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Previous Close:
$1.71
Open:
$1.70
24h Volume:
100,120
Relative Volume:
0.42
Market Cap:
$4.09M
Revenue:
$3,000
Net Income/Loss:
-$4.11M
P/E Ratio:
-
EPS:
-$2.17
Net Cash Flow:
-$3.23M
1W Performance:
-12.50%
1M Performance:
+53.33%
6M Performance:
-38.78%
1Y Performance:
-46.15%
1-Day Range:
$1.60$1.73
1-Week Range:
$1.60$1.89
52-Week Range:
$0.719$4.50
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(346) 355-4099Address
501 E LAS OLAS BLVD, FORT LAUDERDALE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS